论文部分内容阅读
目的评价依达拉奉与奥扎格雷钠联合治疗急性脑梗死的临床疗效。方法选择发病在48 h内的脑梗死患者82例,随机分成治疗组(42例)和对照组(40例)。治疗组给予奥扎格雷钠80 mg+0.9%氯化钠溶液100 ml,1次/d,同时给予依达拉奉30 mg加入0.9%氯化钠溶液100 ml静脉滴注,2次/d,连用14 d;对照组使用同剂量、同疗程的奥扎格雷钠。进行疗效对比分析,同时观察两组治疗前后神经功能缺损程度改变。结果治疗组显效率、总有效率、神经功能缺损程度评分与对照组比较,差异均有统计学意义(P<0.01),两组均无明显不良反应。结论依达拉奉与奥扎格雷钠联合治疗急性脑梗死疗效明显优于单独应用奥扎格雷钠,依达拉奉是治疗急性脑梗死安全有效的药物。
Objective To evaluate the clinical efficacy of edaravone and ozagrel combined in the treatment of acute cerebral infarction. Methods Eighty-two patients with cerebral infarction within 48 hours were randomly divided into treatment group (n = 42) and control group (n = 40). The treatment group was given Ozagrel sodium 80 mg + 0.9% sodium chloride solution 100 ml once a day, at the same time edaravone 30 mg was added to 0.9% sodium chloride solution 100 ml intravenously, 2 times / d, Used for 14 d; control group with the same dose, the same course of ozagrel sodium. Comparative analysis of efficacy, while observing the two groups before and after treatment, the degree of neurological deficit changes. Results The markedly effective rate, total effective rate and neurological deficit score of the treatment group were significantly different from those of the control group (P <0.01). There was no significant adverse reaction in both groups. Conclusion The combination of edaravone and ozagrel sodium in acute cerebral infarction is superior to that of ozagrel sodium alone. Edaravone is a safe and effective drug in the treatment of acute cerebral infarction.